Pharmaceutical companies face tightened scrutiny and a cooling commercial insurance track as Beijing seeks to balance medical innovation with fund sustainability
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China concluded negotiations over drug prices for its 2026 national reimbursement lists on Wednesday, more than a month earlier than in prior years, as Beijing seeks to expand access to innovative medicines while containing pressure on its basic health-insurance fund.
As Chinese drugmakers churn out a record number of novel therapies, industry experts urge an overhaul of pricing, insurance and…
Despite efforts to ease pressure on state-run healthcare, commercial insurers covered just 7.8% of the country’s innovative drug…
The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…
The latest national drug tender seeks to curb destructive price competition while tightening quality requirements for generic…
Multinational drugmakers are returning to China’s centralized procurement program after rule changes gave originator medicines a…
The latest national drug tender seeks to curb destructive price competition while tightening quality requirements for generic…
